Facing erosion of its mighty Eylea (aflibercept) franchise and near-term loss of exclusivity with Dupixent (dupilumab), Regeneron Pharmaceuticals Inc. took a blow as one of two phase III trials with ...

P&G saw three new federal suits that center on allegedly deceptive environmental claims on its Charmin and Puffs paper ...

In the dynamic world of life sciences, companies face unique challenges in safeguarding their valuable assets. From ...

Analyst Brian Abrahams reiterated an Outperform rating and a price target of $943 for Regeneron Pharmaceuticals, Inc. (NASDAQ ...

In the past, most targeted drug development efforts relied on single biomarkers, but cancer is far more complex. BostonGene’s ...

On May 22, 2025, the FDA approved Bio-Thera Solutions and Hikma Pharmaceuticals’ ustekinumab biosimilar, STARJEMZA® (ustekinumab-hmny) ...

The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple ...

West Pharmaceutical Services shares have dropped 35% in 2025, despite better-than-expected Q1 results, with forward guidance ...

Notably, the U.S.’ two primary biopharma trade groups—the Pharmaceutical Research and Manufacturers of America (PhRMA) and ...

LyoWave has also received a $50,000 Phase I grant from the Indiana Economic Development Corp.’s Applied Research Institute.

The Contract Pharma Packaging Market is projected to grow from USD 15.21 billion in 2024 to USD 26.59 billion by 2032, driven by rising outsourcing The U.S. Contract Pharma Packaging Market is booming ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has entered a key licensing agreement with Telesis Bio Inc. to integrate the ...